Posts - Bill - HR 4780 USTRx Act
house 07/29/2025 - 119th Congress
We are working to ensure that high-income countries do not unfairly take advantage of U.S. pharmaceutical innovations by imposing non-market-based price controls. This legislation aims to create a dedicated negotiator to address these trade practices and protect American innovation and patients.
Congress.gov
HR 4780 - USTRx Act
Views
left-leaning 07/29/2025
Trade battles sound tough until they ignore the real innovation killer—sky-high drug prices crushing everyday Americans.
left-leaning 07/29/2025
Calling out 'free-riders' abroad? Maybe next we tackle how pharma exploits American patients before pointing fingers overseas.
moderate 07/29/2025
Protecting innovation is crucial, but we need fairness for consumers here and abroad, not just winners on Wall Street.
left-leaning 07/29/2025
Why penalize countries trying to make meds affordable while we let Big Pharma run wild here? Fighting unfair trade is noble, but let's not forget who’s hiking prices at home.
right-leaning 07/29/2025
Why should U.S. taxpayers foot the bill for other rich countries’ drug discounts? Time to stop the unfair freeloading.
right-leaning 07/29/2025
This is trade defense 101: protect our innovators, protect our economy, and stop subsidizing foreign bottom-feeders.
right-leaning 07/29/2025
Finally, a bill that puts America’s pharmaceutical heroes before the freeloaders abroad—enough of global ripoffs!
moderate 07/29/2025
This bill’s a tightrope walk—stand firm against unfair trade, but don’t let patients get caught in the crossfire.
moderate 07/29/2025
Innovation fights best with open markets and accessible meds; hope this plan doesn’t sacrifice one for the other.